JumpCode Genomics has filed a notice of an exempt offering of securities to raise $11,458,827.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, JumpCode Genomics is raising up to $11,458,827.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, David Salter played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About JumpCode Genomics
Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldnt. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, were broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.
To learn more about JumpCode Genomics, visit http://www.jumpcodegenomics.com/
JumpCode Genomics Linkedin Page: https://www.linkedin.com/company/jumpcodegenomics/
Contact:
David Salter, Chief Executive Officer
619-900-1701
https://www.linkedin.com/in/mike-salter-8577495/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.